Stock market today: S&P 500 rides Apple-led tech rally to close higher
Nicholas B. Hawkins (NASDAQ:HWKN), Vice President and Chief Financial Officer of Arteris , Inc. (NASDAQ:AIP), a company with a market capitalization of $340 million, recently sold a significant portion of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Hawkins sold a total of 5,968 shares on March 3, 2025. InvestingPro data shows the stock has declined over 10% in the past week.
The transactions were conducted in two separate sales. The first involved 468 shares at an average price of $8.3833 per share, totaling approximately $3,923. The second sale, made under a 10b5-1 trading plan adopted in May 2024, included 5,500 shares at a weighted average price of $8.5843, amounting to about $47,213. The shares were sold in multiple transactions at prices ranging from $8.25 to $9.15.
Post-transaction, Hawkins retains ownership of 186,123 shares of Arteris. The initial sale of 468 shares was executed to satisfy tax liabilities arising from the release of restricted stock units.
In other recent news, Arteris, Inc. has been the focus of analyst attention due to its recent financial and strategic developments. Jefferies analyst Blayne Curtis raised the company’s stock price target from $7.00 to $11.00, maintaining a Hold rating. This adjustment reflects Arteris’ progress in the microcontroller unit market, highlighted by a significant win at IFX, and the introduction of the FlexGen solution, which is expected to increase average selling prices by 30% per license. Meanwhile, Northland analysts also increased their price target for Arteris from $14.00 to $16.00, maintaining an Outperform rating. They noted that Arteris reported revenue met expectations, with bookings reaching approximately $33.6 million for the quarter and a book-to-bill ratio of 2.2:1. The FlexNoC 5 product was a standout, accounting for three-quarters of all interconnect licenses. The launch of the FlexGen product, currently being evaluated by 13 customers, has been a significant factor in the revised price targets and is anticipated to positively impact future revenue. Both firms are closely monitoring Arteris’ execution in the MCU market and the potential revenue growth from FlexGen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.